Pyxis Oncology In-Licenses BSI-060T From Biosion for the Treatment of Solid Tumors
- Biosion to receive a $10M up front as license fee & is eligible to receive ~$222.5M in milestone for PYX-106 along with royalties. Pyxis gets an exclusive license to develop & commercialize BSI-060T globally (Ex- Greater China)
- Pyxis is planning to submit the PYX-106’ IND to the US FDA in H2’22 & initiates a P-I trial shortly & gets the rights to license additional preclinical assets that target anti-Siglec-15
- The results from the preclinical studies showed that BSI-060T (anti-Siglec-15 mAb) has high affinity, high cell-binding & activity, dose-proportional activity in reducing immunosuppression of Siglec-15 on T cells & long half-life enables BSI-060T to become a mAb for solid tumors
Ref: PR Newswire | Image: Pyxis
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.